InsiderTrades.com logo
Protect Yourself While There’s Still Time …
From Weiss Ratings   |   Ad
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
4 simple steps to protect your privacy and money before it’s too late.

CLBS Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Caladrius Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Caladrius Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Caladrius Biosciences Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 09/14/2022 06:59 PM ET

This chart shows the closing price history over time for CLBS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Move Your Money Before May 22
From Stansberry Research   |   Ad
The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.
Here's where Dr. David Eifrig says to move your money immediately.

Caladrius Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2021Steven S. MyersDirectorBuy33,785$0.89$30,068.65View SEC Filing Icon  
See Full Table
Move Your Money Before May 22
From Stansberry Research   |   Ad
The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.
Here's where Dr. David Eifrig says to move your money immediately.

SEC Filings (Institutional Ownership Changes) for Caladrius Biosciences (NASDAQ:CLBS)

15.57% of Caladrius Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CLBS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Caladrius Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/8/2022IPG Investment Advisors LLC137,552$73K0.0%N/A0.227%Search for SEC Filing on Google Icon
2/10/2022Alterna Wealth Management Inc.73,000$61K0.1%N/A0.122%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC26,933$33K0.0%N/A0.045%Search for SEC Filing on Google Icon
11/12/2021Renaissance Technologies LLC1,747,055$2.13M0.0%+11.8%2.922%Search for SEC Filing on Google Icon
11/9/2021Barclays PLC21,103$26K0.0%+239.4%0.035%Search for SEC Filing on Google Icon
8/16/2021State Street Corp207,361$0.33M0.0%N/A0.348%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC1,562,832$2.52M0.0%+7.0%2.626%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC372,530$0.60M0.0%+17.1%0.626%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.2,698,035$4.34M0.0%-3.9%4.533%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC44,405$86K0.0%N/A0.075%Search for SEC Filing on Google Icon
5/14/2021Dimensional Fund Advisors LP61,506$0.12M0.0%+199.3%0.103%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC1,460,155$2.82M0.0%+39.6%2.454%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp85,855$0.17M0.0%+398.3%0.144%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC318,153$0.61M0.0%+583.6%0.535%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.1,037,975$2M0.0%+3,340.8%1.745%Search for SEC Filing on Google Icon
4/28/2021Game Plan Financial Advisors LLC15,000$29K0.0%N/A0.025%Search for SEC Filing on Google Icon
3/8/2021Dimensional Fund Advisors LP20,548$29K0.0%-37.1%0.062%Search for SEC Filing on Google Icon
2/25/2021Dimensional Fund Advisors LP20,548$29K0.0%-37.1%0.062%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC52,599$75K0.0%N/A0.160%Search for SEC Filing on Google Icon
2/16/2021Squarepoint Ops LLC20,637$30K0.0%N/A0.063%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC1,045,855$1.50M0.0%+12.8%3.173%Search for SEC Filing on Google Icon
11/9/2020Acadian Asset Management LLC156,668$0.28M0.0%+119.0%0.811%Search for SEC Filing on Google Icon
5/15/2020Summit Trail Advisors LLC17,730$32K0.0%N/A0.138%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Caladrius Biosciences logo
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Read More on Caladrius Biosciences

Today's Range

Now: N/A

50 Day Range

MA: $6.37
Low: $0.43
High: $8.38

52 Week Range

Now: N/A

Volume

466,373 shs

Average Volume

522,308 shs

Market Capitalization

$26.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91
Protect Yourself While There’s Still Time …
From Weiss Ratings   |   Ad
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
4 simple steps to protect your privacy and money before it’s too late.